SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rozpoznaniem raka płuca (nie-drobnokomórkowego) o wysokiej aktywności
- •Zaplanowana radioterapia klatki piersiowej (lecznicza lub paliatywna)
✗ Disqualifies
- •Rak płuca o małych komórkach
- •Poważne choroby serca (zaburzenia rytmu, zawał w ostatnich 6 miesiącach)
- •Ciąża, karmienie piersią lub brak chęci stosowania antykoncepcji
- •Uczestniczenie w innych badaniach klinicznych
- •Inne warunki uznane przez lekarza za uniemożliwiające uczestnictwo
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.